Interleukin-1β induces an inflammatory response and the breakdown of the endothelial cell layer in an improved human THBMEC-based in vitro blood-brain barrier model

Journal of Neuroscience Methods

Volumn 228, Issue , 2014, Pages 35-45

  Labus, Josephine ^a   Häckel, Sonja ^a   Lucka, Lother ^a   Danker, Kerstin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood brain barrier; Inflammation; Interleukin 1 ; THBMEC; Transmigration; Transwell model

Indexed keywords

FLUORESCEIN SODIUM; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA; ACTIN; CULTURE MEDIUM; CYTOKINE; OCCLUDIN; TJP1 PROTEIN, HUMAN; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; MICROVASCULAR ENDOTHELIAL CELL; NERVOUS SYSTEM INFLAMMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOLOGICAL MODEL; CAPILLARY PERMEABILITY; CULTURE MEDIUM; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; IMPEDANCE; METABOLISM; PHARMACOLOGY; PHYSIOLOGY; TIME; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TRANSFORMED CELL LINE;

ACTINS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL LINE, TRANSFORMED; CULTURE MEDIA; CYTOKINES; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IN VITRO TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; LEUKOCYTES; MODELS, BIOLOGICAL; OCCLUDIN; TIME FACTORS; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULAR CELL ADHESION MOLECULE-1; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84897845208     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2014.03.002     Document Type: Article

References (51)

1. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002, 200(6):629-638.
2. Argaw A.T., Zhang Y., Snyder B.J., Zhao M.L., Kopp N., Lee S.C., et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 2006, 177(8):5574-5584.
3. Basu A., Krady J.K., Levison S.W. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 2004, 78(2):151-156.
4. Bernacki J., Dobrowolska A., Nierwinska K., Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008, 60(5):600-622.
5. Blasig I.E., Giese H., Schroeter M.L., Sporbert A., Utepbergenov D.I., Buchwalow I.B., et al. *NO and oxyradical metabolism in new cell lines of rat brain capillary endothelial cells forming the blood-brain barrier. Microvasc Res 2001, 62(2):114-127.
6. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 2006, 108(2):124-128.
7. Brown R.C., Morris A.P., O'Neil R.G. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007, 1130(1):17-30.
8. Cacabelos R., Franco-Maside A., Alvarez X.A. Interleukin-1 in Alzheimer's disease and multi-infarct dementia: neuropsychological correlations. Method Find Exp Clin 1991, 13(10):703-708.
9. Callahan M.K., Williams K.A., Kivisakk P., Pearce D., Stins M.F., Ransohoff R.M. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J Neuroimmunol 2004, 153(1-2):150-157.
10. Cohen-Kashi Malina K., Cooper I., Teichberg V.I. Closing the gap between the in-vivo and in-vitro blood-brain barrier tightness. Brain Res 2009, 1284:12-21.
11. Coisne C., Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal 2011, 15(5):1285-1303.
12. Daniels B.P., Cruz-Orengo L., Pasieka T.J., Couraud P.O., Romero I.A., Weksler B., et al. Immortalized human cerebral microvascular endothelial cells maintain the properties of primary cells in an in vitro model of immune migration across the blood brain barrier. J Neurosci Methods 2013, 212(1):173-179.
13. Deb S., Gottschall P.E. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 1996, 66(4):1641-1647.
14. Deli M.A., Abraham C.S., Kataoka Y., Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005, 25(1):59-127.
15. Engelhardt B. Development of the blood-brain barrier. Cell Tissue Res 2003, 314(1):119-129.
16. Ferreira A.M., McNeil C.J., Stallaert K.M., Rogers K.A., Sandig M. Interleukin-1beta reduces transcellular monocyte diapedesis and compromises endothelial adherens junction integrity. Microcirculation 2005, 12(7):563-579.
17. Griep L.M., Wolbers F., de Wagenaar B., ter Braak P.M., Weksler B.B., Romero I.A., et al. BBB ON CHIP: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed Microdevices 2013, 15(1):145-150.
18. Griffiths M., Neal J.W., Gasque P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int Rev Neurobiol 2007, 82:29-55.
19. Gumbleton M., Audus K.L. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 2001, 90(11):1681-1698.
20. Hatherell K., Couraud P.O., Romero I.A., Weksler B., Pilkington G.J. Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods 2011, 199(2):223-229.
21. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57(2):173-185.
22. Hawkins R.A., O'Kane R.L., Simpson I.A., Vina J.R. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 2006, 136(1 Suppl):218S-226S.
23. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999, 19(9):3440-3447.
24. Joo F. The cerebral microvessels in culture, an update. J Neurochem 1992, 58(1):1-17.
25. Kataoka T. Chemical biology of inflammatory cytokine signaling. J Antibiot (Tokyo) 2009, 62(12):655-667.
26. Lucas S.M., Rothwell N.J., Gibson R.M. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006, 147(Suppl. 1):S232-S240.
27. Man S., Ubogu E.E., Williams K.A., Tucky B., Callahan M.K., Ransohoff R.M. Human brain microvascular endothelial cells and umbilical vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration. Clin Dev Immunol 2008, 2008:384982.
28. Man S., Tucky B., Bagheri N., Li X., Kochar R., Ransohoff R.M. alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions. J Neuroimmunol 2009, 210:92-99.
29. Merrill J.E., Murphy S.P. Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav Immun 1997, 4:245-263.
30. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003, 9(6):540-549.
31. More S.V., Kumar H., Kim I.S., Song S.Y., Choi D.K. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm 2013, 2013:952375.
32. Qin W., Lu W., Li H., Yuan X., Li B., Zhang Q., et al. Melatonin inhibits IL1beta-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NF-kappaB activation. J Endocrinol 2012, 214(2):145-153.
33. Rigor R.R., Beard R.S., Litovka O.P., Yuan S.Y. Interleukin-1beta-induced barrier dysfunction is signaled through PKC-theta in human brain microvascular endothelium. Am J Physiol Cell Physiol 2012, 302(10):C1513-C1522.
34. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009, 8(2):205-216.
35. Rothwell N.J., Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000, 23(12):618-625.
36. Santaguida S., Janigro D., Hossain M., Oby E., Rapp E., Cucullo L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res 2006, 1109(1):1-13.
37. Sawada N., Murata M., Kikuchi K., Osanai M., Tobioka H., Kojima T., et al. Tight junctions and human diseases. Med Electron Microsc 2003, 36(3):147-156.
38. Shaftel S.S., Griffin W.S., O'Banion M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflamm 2008, 5:7.
39. Simi A., Tsakiri N., Wang P., Rothwell N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 2007, 35(Pt 5):1122-1126.
40. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010, 10(10):712-723.
41. Stamatovic S.M., Keep R.F., Andjelkovic A.V. Brain endothelial cell-cell junctions: how to open the blood brain barrier. Curr Neuropharmacol 2008, 6(3):179-192.
42. Steiner O., Coisne C., Engelhardt B., Lyck R. Comparison of immortalized bEnd5 and primary mouse brain microvascular endothelial cells as in vitro blood-brain barrier models for the study of T cell extravasation. J Cereb Blood Flow Metab 2011, 31(1):315-327.
43. Stephan D., Sbai O., Wen J., Couraud P.O., Putterman C., Khrestchatisky M., et al. TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. J Neuroinflamm 2013, 10:9.
44. Stins M.F., Badger J., Sik Kim K. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb Pathog 2001, 30(1):19-28.
45. Takeshita Y., Ransohoff R.M. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 2012, 248(1):228-239.
46. Ubogu E.E., Callahan M.K., Tucky B.H., Ransohoff R.M. CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro. Cell Immunol 2006, 243(1):19-29.
47. Ubogu E.E., Callahan M.K., Tucky B.H., Ransohoff R.M. Determinants of CCL5-driven mononuclear cell migration across the blood-brain barrier. Implications for therapeutically modulating neuroinflammation. J Neuroimmunol 2006, 179(1-2):132-144.
48. Wilhelm I., Fazakas C., Krizbai I.A. In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Warsz) 2011, 71(1):113-128.
49. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38(6):323-337.
50. Yuan X., Li B., Li H., Xiu R. Melatonin inhibits IL-1beta-induced monolayer permeability of human umbilical vein endothelial cells via Rac activation. J Pineal Res 2011, 51(2):220-225.
51. Zozulya A., Weidenfeller C., Galla H.J. Pericyte-endothelial cell interaction increases MMP-9 secretion at the blood-brain barrier in vitro. Brain Res 2008, 1189:1-11.